Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTISTRY-6: Nemvaleukin alfa in advanced melanoma after anti-PD-[L]1 therapy
2021-001557-31Phase 2Active
- Sponsor
- Alkermes
- Start
- Nov 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of nemvaleukin alfa in cutaneous melanoma (CM), mucosal melanoma (MM) and melanoma (2 cohorts), sponsored by Alkermes. Primary endpoint: Centrally-assessed overall response rate (ORR) by RECIST 1.1. Started Nov 2021; status: active.
02
Drugs
nemvaleukin alfa
03
Conditions
cutaneous melanoma (CM)mucosal melanoma (MM)melanoma
Beyond the preview
Go deeper on 2021-001557-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001557-31.